Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Candel Therapeutics (CADL) Shares Outstanding (2020 - 2025)

Candel Therapeutics' Shares Outstanding history spans 4 years, with the latest figure at $29.2 million for Q4 2023.

  • On a quarterly basis, Shares Outstanding rose 0.59% to $29.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was $29.2 million, a 0.59% increase, with the full-year FY2023 number at $29.2 million, up 0.59% from a year prior.
  • Shares Outstanding hit $29.2 million in Q4 2023 for Candel Therapeutics, up from -$122608.0 in the prior quarter.
  • Over the last five years, Shares Outstanding for CADL hit a ceiling of $29.2 million in Q4 2023 and a floor of -$122608.0 in Q3 2022.
  • Historically, Shares Outstanding has averaged $17.4 million across 4 years, with a median of $11.7 million in 2021.
  • Biggest five-year swings in Shares Outstanding: soared 147.01% in 2021 and later plummeted 101.05% in 2022.
  • Tracing CADL's Shares Outstanding over 4 years: stood at $11.6 million in 2020, then soared by 146.58% to $28.7 million in 2021, then grew by 1.23% to $29.0 million in 2022, then rose by 0.59% to $29.2 million in 2023.
  • Business Quant data shows Shares Outstanding for CADL at $29.2 million in Q4 2023, $29.0 million in Q3 2023, and -$122608.0 in Q2 2023.